Sugi Predict

Sugi Predict / Compounds / SCHEMBL2921637

SCHEMBL2921637

SCHEMBL2921637

CC(C)(C)OC(=O)N1CCc2sc(CO)cc2C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.52
▸ NR1H2 P55055 1/20 0.51
▸ BRD4 O60885 1/20 0.48
▸ CREBBP Q92793 1/20 0.48
▸ ADORA1 P30542 2/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ MAPT P10636 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ NAMPT P43490 1/20 0.40
▸ SLC5A1 P13866 1/20 0.40
▸ SLC5A2 P31639 1/20 0.40
▸ P2RX3 P56373 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ GRAMD1A Q96CP6 1/20 0.38
▸ MKNK1 Q9BUB5 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8556789 0.90 ESR2 (0.50) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL27141188 0.90 ESR2 (0.52) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL12393136 0.90 ESR2 (0.52) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL6198277 0.89 NR1H2 (0.53) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL23452343 0.88 ESR2 (0.43) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL7992597 0.88 ESR2 (0.50) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL19539155 0.87 ESR2 (0.49) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL5548036 0.86 ESR2 (0.48) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL12340040 0.85 ESR2 (0.47) ESR2NR1H2BRD4CREBBPADORA1
SCHEMBL5548939 0.85 ESR2 (0.47) ESR2NR1H2BRD4CREBBPADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011323-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2025-01-09 — — US disclosed
US-20240391917-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2024-11-28 — — US disclosed
US-12110288-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-10-08 — — US disclosed
EP-4069238-A1 MASP-2 INHIBITORS AND METHODS OF USE Omeros Corporation (US) 2022-10-12 — — EP disclosed
CN-115052604-A MASP-2 inhibitors and methods of use 奥默罗斯公司 2022-09-13 — — CN disclosed
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-17 — — US disclosed
WO-2021113686-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2021-06-10 — — WO disclosed
US-8268814-B2 Substituted sulfonamide compounds GRUENENTHAL GMBH (DE) 2012-09-18 — — US disclosed
EP-2260043-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal Gmbh (DE) 2010-12-15 — — EP disclosed
US-7812014-B2 Bicyclic 6-alkylidene-penems as β-lactamase inhibitors WYETH LLC (US) 2010-10-12 — — US disclosed
US-20030232808-A1 Sulfonyl derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-12-18 — — US disclosed
WO-2003093279-A1 BICYCLIC 6-ALKYLIDENE-PENEMS AS ß-LACTAMASES INHIBITORS WYETH (US) 2003-11-13 — — WO disclosed
WO-2003093277-A1 PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES WYETH (US) 2003-11-13 — — WO disclosed
US-6525042-B1 Inhibits an activated coagulation factor FXa; anticoagulant, antithrombotic DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-02-25 — — US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 — — EP disclosed
EP-1031563-A1 SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2000-08-30 — — EP disclosed
EP-0641770-B1 NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY MEIJI SEIKA CO (JP) 1998-05-13 — — EP disclosed
US-5698692-A INHIBIT BINDING BETWEEN PLATELET MEMBRANE GLYCOPROTEIN AND FIBRINOGEN MEIJI SEIKA KABUSHIKI KAISHA (JP) 1997-12-16 — — US disclosed
US-5594004-A CARDIOVASCULAR DISORDERS AND ANTICOAGULANTS MEIJI SEIKA KABUSHIKI KAISHA (JP) 1997-01-14 — — US disclosed
EP-0641770-A1 NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY MEIJI SEIKA KABUSHIKI KAISHA (JP) 1995-03-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12110288-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 ESR2 2756/4885NR1H2 4695/4885BRD4 1233/4885
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ESR2 2756/4885NR1H2 4695/4885BRD4 1233/4885
US-20030232808-A1 Sulfonyl derivatives SULT1E1, SULT2A1, SULT1A1 ESR2 897/4885NR1H2 73/4885BRD4 1843/4885
US-20250011323-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ESR2 2756/4885NR1H2 4695/4885BRD4 1233/4885
US-20240391917-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ESR2 2756/4885NR1H2 4695/4885BRD4 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.